Clinical Trials
3 trialsNCT06613633 2026-04-29
Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC
Fudan University
Completed
NCT06812871 2026-04-02
High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis
Sun Yat-sen University
Phase 2 Completed
NCT05465343 2025-12-19
Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)
Peking Union Medical College
Phase 2 Completed